Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Research Use Only Disclaimer Research Use Only: All SaiyanMed products are intended and labeled solely for laboratory research use
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Western Europe: In Western Europe, Germany is a key market for GLP-1 receptor agonists, driven by the growing demand for effective diabetes treatments and the countrys strong healthcare system
Metal ions in life sciences
9:00 18:00
/assets/images/provider/photos/2775905.jpeg)
